Home Cart Sign in  
Chemical Structure| 324523-20-8 Chemical Structure| 324523-20-8

Structure of NPS-2143 HCl
CAS No.: 324523-20-8

Chemical Structure| 324523-20-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NPS-2143 hydrochloride (SB-262470A hydrochloride), an orally active calcilytic agent, is a selective and potent calcium ion-sensing receptor (CaSR) antagonist. NPS-2143 hydrochloride (SB-262470A hydrochloride) blocks increases in cytoplasmic Ca2+ concentrations (IC50=43 nM) elicited by activating the Ca2+ receptor in HEK 293 cells expressing the human Ca2+ receptor.

Synonyms: SB-262470A hydrochloride; NPS 2143 (hydrochloride); SB-262470A

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NPS-2143 HCl

CAS No. :324523-20-8
Formula : C24H26Cl2N2O2
M.W : 445.38
SMILES Code : N#CC1=C(OC[C@@H](CNC(C)(C)CC2=CC=C3C=CC=CC3=C2)O)C=CC=C1Cl.[H]Cl
Synonyms :
SB-262470A hydrochloride; NPS 2143 (hydrochloride); SB-262470A
MDL No. :N/A
InChI Key :ZEBNDUQLNGYBNL-VEIFNGETSA-N
Pubchem ID :9868131

Safety of NPS-2143 HCl

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H372-H410
Precautionary Statements:P501-P273-P260-P270-P264-P280-P391-P314-P337+P313-P305+P351+P338-P301+P312+P330
Class:9
UN#:3077
Packing Group:

Related Pathways of NPS-2143 HCl

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
renal carcinoma cells 5 μM 1 hour Inhibit CaSR, reduce calcium-induced cell migration and proliferation PMC3945739
HEK293T cells 30 µM 1 hour To measure the negative allosteric modulation effect of NPS-2143 on ggCaSR, results showed that NPS-2143 significantly inhibited the activity of ggCaSR. PMC8177707
HEK293 cells 20 nM and 40 nM 1 hour NPS-2143 at 20 nM concentration increased the EC50 of Val62 Gα11 mutant cells to 2.97 mM, which was not significantly different from untreated WT cells. At 40 nM concentration, the EC50 of mutant cells increased to 3.48 mM, which was significantly higher than untreated WT cells. PMC5291742
Human aortic endothelial cells (HAoECs) 1 μM 1 hour To verify the role of NPS-2143 in inhibiting γ-EV-mediated CaSR activation, the results showed that NPS-2143 reversed the γ-EV-mediated reduction of VCAM-1 and E-selectin, suggesting that the anti-inflammatory effect of γ-EV might be through CaSR-dependent pathways. PMC8012099
IPEC-J2 cells 6 µM 1 hour NPS2143 reversed the enhancement effect of tryptophan on the protein concentrations of ZO-1, occludin, claudin-1, and CaSR, significantly reduced the TEER value, and increased the permeability of FITC-dextran PMC8566706
HEK-CASR cells 10, 20, 30 nM 1 hour To investigate whether allosteric inhibition of the CASR might rectify the gain-of-function effect imposed by the GNA11R6OC mutation, the effect of the NPS 2143 calcilytic compound on CASR signaling was examined in HEK-CASR cells expressing either WT Gα11 or mutant (Cys60) Gα11 proteins. NPS 2143 increased the EC50 of Gα11-Cys60–expressing mutant cells in a dose-dependent manner, shifting the calcium response curve towards WT levels. PMC5291736
PC12 cells 25 μM 24 hours To investigate the protective effect of NPS-2143 on PC12 cells in the oxygen-glucose deprivation/reoxygenation (OGD/R) model. The results showed that NPS-2143 significantly improved cell viability and inhibited the apoptotic rate. PMC7723498
Human cortical astrocytes 100 nM 30 minutes NPS 2143 totally suppressed the oversecretion of IL-6 and remarkably reduced the over-release of other inflammatory agents. PMC7349863
IPAH-PASMC 10 μM NPS-2143 significantly inhibited the extracellular Ca2+-mediated increase in [Ca2+]cyt in IPAH-PASMC PMC3695473
HEK 293 cells 43 nM Identified a compound that inhibits increases in cytoplasmic Ca2+ levels and further optimized to yield NPS 2143 PMC300853
Bovine parathyroid cells 39 nM NPS 2143 stimulated PTH secretion from bovine parathyroid cells PMC300853

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CaR wild-type and CaR-null mice Intravenous injection 1 mg/kg Single dose, gavage performed 30 minutes post-injection To evaluate the inhibitory effect of NPS 2143 on CaR, results showed that NPS 2143 completely inhibited gastrin secretion. PMC2955134
rats MCT-induced pulmonary hypertension model intraperitoneal injection 4.5 mg/kg/day once daily for 10 days NPS-2143 significantly inhibited the development of MCT-induced pulmonary hypertension and right ventricular hypertrophy PMC3695473
Rats Osteoporosis model (OVX rats) Oral 100 mmol/kg Daily for 8 weeks NPS 2143 caused a sustained increase in plasma PTH levels, provoking a dramatic increase in bone turnover but no net change in bone mineral density PMC300853
Mice Dsk7 mouse model Oral gavage 100 μmol/kg single dose NPS-2143 significantly increased plasma PTH concentrations in Dsk7/+ and Dsk7/Dsk7 mice and rectified or improved their hypocalcemia. PMC5291742
Mice GNA11R60C mutant mouse model intraperitoneal injection 28 mg/kg single injection, observed at 4 and 24 hours To investigate the therapeutic effect of NPS 2143 on GNA11R60C mutant mice, the results showed that NPS 2143 significantly increased serum calcium and PTH levels, suggesting its potential for treating ADH2. PMC5291736
Rats Middle cerebral artery occlusion/reperfusion (MCAO/R) model Intraperitoneal injection 10 µmol/kg Single injection, lasting 24 hours To investigate the neuroprotective effect of NPS-2143 on MCAO/R model rats. The results showed that NPS-2143 significantly reduced neurological function scores and cerebral infarction volume. PMC7723498

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.25mL

0.45mL

0.22mL

11.23mL

2.25mL

1.12mL

22.45mL

4.49mL

2.25mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories